肾癌HSP70-PC体外诱导DC成熟激活特异性抗肿瘤免疫的作用

来源 :中国医学工程 | 被引量 : 0次 | 上传用户:gao_zhenguo
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的研究肾癌细胞株中纯化的HSP70-PC体外诱导DC成熟及激活特异性抗肿瘤免疫的作用。方法采用亲和层析及离子交换层析法纯化肾癌细胞HSP70-PC,体外致敏DC,流式细胞仪检测DC表型变化,用DC体外诱导CTL产生,MTT法比较其对不同肿瘤细胞的杀伤活性。结果HSP70-PC和TNF-α均能使DC高表达分化相关抗原CD1a、CD83、HLA-DR,肾癌细胞中纯化的HSP70-PC致敏的DC体外诱导的CTL对肾癌细胞有较高的杀伤活性。结论肾癌细胞中纯化的HSP70-PC能有效地诱导DC成熟,并使其具有活化针对肾癌细胞的特异性CTL的能力。 Objective To investigate the role of purified HSP70-PC in renal cell carcinoma in vitro to induce DC maturation and activate specific anti-tumor immunity. Methods The renal carcinoma HSP70-PC was purified by affinity chromatography and ion exchange chromatography. The DCs were sensitized in vitro. The phenotypic changes of DCs were detected by flow cytometry. CTLs were induced by DC in vitro. MTT assay was used to compare the expression of HSP70- The killing activity. Results Both HSP70-PC and TNF-α could induce high expression of CD1a, CD83 and HLA-DR in DCs. CTL induced by HSP70-PC sensitized DCs in renal cancer cells had a higher Killing activity. Conclusion Purified HSP70-PC in renal cancer cells can effectively induce DC maturation and make it have the ability to activate specific CTLs against renal cancer cells.
其他文献
目的 探讨血浆置换治疗移植肾复发性局灶性节段性肾小球硬化(FSGS)效果及其对远期预后的影响.方法6例患者首次肾移植后出现大量蛋白尿或/和血肌酐(Cr)升高、并经移植肾活检确诊为FSGS,在不改变免疫抑制方案的情况下,采用血浆置换治疗,观察血浆置换后1年移植肾的病理改变情况,测定血肌酐和24 h尿蛋白定量.结果6例患者中,2例在血浆置换后1年接近完全缓解,4例部分缓解.患者血浆置换后1年,移植肾的